AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity

Cancer Cell

Volumn 19, Issue 1, 2011, Pages 58-71

  Chandarlapaty, Sarat ^a   Sawai, Ayana ^a   Scaltriti, Maurizio ^b   Rodrik Outmezguine, Vanessa ^a   Grbovic Huezo, Olivera ^a   Serra, Violeta ^b   Majumder, Pradip K ^c   Baselga, Jose ^b   Rosen, Neal ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEFITINIB; INSULIN RECEPTOR; LAPATINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN; PROTEIN HER3; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PROTEIN MTORC1; PROTEIN TYROSINE KINASE; SOMATOMEDIN C RECEPTOR; TRANSCRIPTION FACTOR FOXO; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; MOUSE; NEGATIVE FEEDBACK; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE DRUG DOSE;

EID: 78651458656     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2010.10.031     Document Type: Article

References (35)

1. Amin D.N., Sergina N., Ahuja D., McMahon M., Blair J.A., Wang D., Hann B., Koch K.M., Shokat K.M., Moasser M.M. Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Sci Transl. Med. 2010, 2:16ra17.
2. Ayala J.E., Streeper R.S., Desgrosellier J.S., Durham S.K., Suwanichkul A., Svitek C.A., Goldman J.K., Barr F.G., Powell D.R., O'Brien R.M. Conservation of an insulin response unit between mouse and human glucose-6-phosphatase catalytic subunit gene promoters: transcription factor FKHR binds the insulin response sequence. Diabetes 1999, 48:1885-1889.
3. Barnett S.F., Defeo-Jones D., Fu S., Hancock P.J., Haskell K.M., Jones R.E., Kahana J.A., Kral A.M., Leander K., Lee L.L., et al. Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem. J. 2005, 385:399-408.
4. Basso A.D., Solit D.B., Munster P.N., Rosen N. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene 2002, 21:1159-1166.
5. Brunet A., Bonni A., Zigmond M.J., Lin M.Z., Juo P., Hu L.S., Anderson M.J., Arden K.C., Blenis J., Greenberg M.E. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999, 96:857-868.
6. Brunn G.J., Hudson C.C., Sekulic A., Williams J.M., Hosoi H., Houghton P.J., Lawrence J.C., Abraham R.T. Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science 1997, 277:99-101.
7. Buck E., Eyzaguirre A., Rosenfeld-Franklin M., Thomson S., Mulvihill M., Barr S., Brown E., O'Connor M., Yao Y., Pachter J., et al. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res. 2008, 68:8322-8332.
8. Courtney K.D., Corcoran R.B., Engelman J.A. The PI3K pathway as drug target in human cancer. J. Clin. Oncol. 2010, 28:1075-1083.
9. Courtois-Cox S., Genther Williams S.M., Reczek E.E., Johnson B.W., McGillicuddy L.T., Johannessen C.M., Hollstein P.E., MacCollin M., Cichowski K. A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell 2006, 10:459-472.
10. DeFeo-Jones D., Barnett S.F., Fu S., Hancock P.J., Haskell K.M., Leander K.R., McAvoy E., Robinson R.G., Duggan M.E., Lindsley C.W., et al. Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members. Mol. Cancer Ther. 2005, 4:271-279.
11. Guertin D.A., Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell 2007, 12:9-22.
12. Haruta T., Uno T., Kawahara J., Takano A., Egawa K., Sharma P.M., Olefsky J.M., Kobayashi M. A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. Mol. Endocrinol. 2000, 14:783-794.
13. Hermanto U., Zong C.S., Wang L.H. ErbB2-overexpressing human mammary carcinoma cells display an increased requirement for the phosphatidylinositol 3-kinase signaling pathway in anchorage-independent growth. Oncogene 2001, 20:7551-7562.
14. Holbro T., Beerli R.R., Maurer F., Koziczak M., Barbas C.F., Hynes N.E. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc. Natl. Acad. Sci. USA 2003, 100:8933-8938.
15. Hynes N.E., Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 2005, 5:341-354.
16. Karaman M.W., Herrgard S., Treiber D.K., Gallant P., Atteridge C.E., Campbell B.T., Chan K.W., Ciceri P., Davis M.I., Edeen P.T., et al. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 2008, 26:127-132.
17. Kaushansky A., Gordus A., Budnik B.A., Lane W.S., Rush J., MacBeath G. System-wide investigation of ErbB4 reveals 19 sites of Tyr phosphorylation that are unusually selective in their recruitment properties. Chem. Biol. 2008, 15:808-817.
18. Kenyon C., Chang J., Gensch E., Rudner A., Tabtiang R. A C. elegans mutant that lives twice as long as wild type. Nature 1993, 366:461-464.
19. Kooijman R., Lauf J.J., Kappers A.C., Rijkers G.T. Insulin-like growth factor induces phosphorylation of immunoreactive insulin receptor substrate and its association with phosphatidylinositol-3 kinase in human thymocytes. J. Exp. Med. 1995, 182:593-597.
20. Kops G.J., de Ruiter N.D., De Vries-Smits A.M., Powell D.R., Bos J.L., Burgering B.M. Direct control of the Forkhead transcription factor AFX by protein kinase B. Nature 1999, 398:630-634.
21. Lindsley C.W., Zhao Z., Leister W.H., Robinson R.G., Barnett S.F., Defeo-Jones D., Jones R.E., Hartman G.D., Huff J.R., Huber H.E., Duggan M.E. Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. Bioorg. Med. Chem. Lett. 2005, 15:761-764.
22. Mellinghoff I.K., Wang M.Y., Vivanco I., Haas-Kogan D.A., Zhu S., Dia E.Q., Lu K.V., Yoshimoto K., Huang J.H., Chute D.J., et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 2005, 353:2012-2024.
23. Myatt S.S., Lam E.W. The emerging roles of forkhead box (Fox) proteins in cancer. Nat. Rev. Cancer 2007, 7:847-859.
24. O'Reilly K.E., Rojo F., She Q.B., Solit D., Mills G.B., Smith D., Lane H., Hofmann F., Hicklin D.J., Ludwig D.L., et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006, 66:1500-1508.
25. Okuzumi T., Fiedler D., Zhang C., Gray D.C., Aizenstein B., Hoffman R., Shokat K.M. Inhibitor hijacking of Akt activation. Nat. Chem. Biol. 2009, 5:484-493.
26. Pratilas C.A., Taylor B.S., Ye Q., Viale A., Sander C., Solit D.B., Rosen N. (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc. Natl. Acad. Sci. USA 2009, 106:4519-4524.
27. Puig O., Tjian R. Transcriptional feedback control of insulin receptor by dFOXO/FOXO1. Genes Dev. 2005, 19:2435-2446.
28. Sergina N.V., Rausch M., Wang D., Blair J., Hann B., Shokat K.M., Moasser M.M. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007, 445:437-441.
29. She Q.B., Chandarlapaty S., Ye Q., Lobo J., Haskell K.M., Leander K.R., DeFeo-Jones D., Huber H.E., Rosen N. Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS ONE 2008, 3:e3065.
30. Solit D.B., Garraway L.A., Pratilas C.A., Sawai A., Getz G., Basso A., Ye Q., Lobo J.M., She Y., Osman I., et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006, 439:358-362.
31. Stommel J.M., Kimmelman A.C., Ying H., Nabioullin R., Ponugoti A.H., Wiedemeyer R., Stegh A.H., Bradner J.E., Ligon K.L., Brennan C., et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007, 318:287-290.
32. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2002, 2:489-501.
33. von Manteuffel S.R., Dennis P.B., Pullen N., Gingras A.C., Sonenberg N., Thomas G. The insulin-induced signalling pathway leading to S6 and initiation factor 4E binding protein 1 phosphorylation bifurcates at a rapamycin-sensitive point immediately upstream of p70s6k. Mol. Cell. Biol. 1997, 17:5426-5436.
34. Workman P., Clarke P.A., Raynaud F.I., van Montfort R.L. Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Cancer Res. 2010, 70:2146-2157.
35. Yakes F.M., Chinratanalab W., Ritter C.A., King W., Seelig S., Arteaga C.L. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res. 2002, 62:4132-4141.